VLP

HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Wednesday, March 20, 2024
Research, MD, Infant, Vaccine, VLP, Gastroenteritis, Growth, G&A, Doctor of Philosophy, Pharmaceutical industry

BOSTON, March 20, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the year ended December 31, 2023, highlighted recent progress and outlined key upcoming milestones for HIL-214, the company’s investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis.

Key Points: 
  • “Over the past year, we made significant progress with HIL-214, our vaccine candidate for the prevention of moderate-to-severe norovirus related acute gastroenteritis.
  • As of October 2023, HilleVax has completed enrollment of subjects in all three clinical trials.
  • As of December 31, 2023 and December 31, 2022, the company had cash, cash equivalents and marketable securities totaling $303.5 million and $279.4 million, respectively.
  • Other income for the fourth quarter 2023 was $3.3 million, compared to $1.9 million for the fourth quarter 2022.

Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Hypersensitivity, Pregnancy, Wart, Head, Congress, Recombinant, Multiple endocrine neoplasia, Dizziness, Safety, Vain, Headache, Bruise, Public, Syncope, Ageing, Merck & Co., Cervical intraepithelial neoplasia, Vulvar intraepithelial neoplasia, Anal cancer, Virus-like particle, Observation, CIN, Thigh, Human, HPV, Plant, Vaginal intraepithelial neoplasia, Nausea, MRK, VLP, Investment, Immunity, Fever, Erythema, Vaccination, Injury, Vaccine, Allergy, Itch, AIN, Swelling

Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.

Key Points: 
  • Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • The latest addition to the pipeline employs the company’s proprietary virus-like particle (VLP) technology to incorporate additional VLPs for expanded HPV type coverage.
  • These randomized, double-blind, multi-year clinical trials will examine the short and long-term efficacy and immunogenicity of a single-dose of GARDASIL 9 versus the currently approved three-dose regimen.

Luca Mining Reports Record Production at Tahuehueto, Consistent Positive Operating Cash Flow Achieved at Campo Morado, Management Updates and Retention of Market Maker

Retrieved on: 
Monday, March 4, 2024
Copper, TSX Venture Exchange, Zinc, Interim, Lead, Ausenco, Gold, Family, VLP, Management

VANCOUVER, BC, March 4, 2024 /PRNewswire/ - Luca Mining Corp. ("Luca" or the "Company") (TSXV: LUCA) (OTCQX: LUCMF) (Frankfurt: Z68) reports the following updates on its operations in Mexico and Management changes.

Key Points: 
  • VANCOUVER, BC, March 4, 2024 /PRNewswire/ - Luca Mining Corp. ("Luca" or the "Company") (TSXV: LUCA) (OTCQX: LUCMF) (Frankfurt: Z68) reports the following updates on its operations in Mexico and Management changes.
  • The mine achieved a new daily production record of 655 tonnes this week.
  • We are pleased to announce that Campo Morado is now consistently generating positive operating cash flow.
  • Concurrently, Campo Morado has been transformed into a positive cash flowing asset with substantial upside as a copper-zinc producer.

Italian Engineering Firm VLP and Partners Uses Dassault Systèmes’ 3DEXPERIENCE Platform to Manage Complex Architectural Projects

Retrieved on: 
Thursday, February 8, 2024
Technology, Engineering, Architecture, Other Professional Services, Manufacturing, Professional Services, Construction & Property, Other Technology, Software, Internet, Other Manufacturing, Electronic Design Automation, Data Management, Steel, Multimedia, Knowledge, VLP, Element, 3D, Partner, Euronext Paris, Product lifecycle, PLM, Dassault Group, Construction

Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) today announced that VLP and Partners , an Italian construction engineering firm specializing in the design of complex facades and steel structures, is using Dassault Systèmes' 3DEXPERIENCE platform on the cloud to manage large and increasingly complex architectural projects.

Key Points: 
  • Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) today announced that VLP and Partners , an Italian construction engineering firm specializing in the design of complex facades and steel structures, is using Dassault Systèmes' 3DEXPERIENCE platform on the cloud to manage large and increasingly complex architectural projects.
  • After years of using Dassault Systèmes' design applications, VLP and Partners began using the “ From Experience to Construction ” industry solution experience based on the 3DEXPERIENCE platform to manage designs and projects in a single virtual environment and collaboratively solve any type of architectural and engineering challenge.
  • The implementation in the cloud allowed VLP and Partners to be immediately operational on the 3DEXPERIENCE platform, without the need for a physical IT infrastructure.
  • Dassault Systèmes’ industry solution experiences for Architecture, Engineering and Construction: https://www.3ds.com/industries/architecture-engineering-construction
    Dassault Systèmes’ 3DEXPERIENCE platform, 3D design software, 3D Digital Mock Up and Product Lifecycle Management (PLM) solutions: http://www.3ds.com

HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference

Retrieved on: 
Monday, February 5, 2024
Death, VLP, AGE, Norovirus, Vaccine

HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines.

Key Points: 
  • HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines.
  • Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
  • The burden of norovirus falls disproportionately on young children and older adults.
  • For more information about HilleVax, visit the company’s website at http://www.HilleVax.com.

Renesas Launches RZ/G3S 64-bit Microprocessor with Enhanced Peripherals for IoT Edge and Gateway Devices

Retrieved on: 
Tuesday, January 16, 2024
Technology, Mobile, Wireless, Semiconductor, 5G, Security, Software, Hardware, IOT (Internet of Things), Data Management, ECC, Gigabit Ethernet, UART, MPU, Hertz, Renesas Electronics, DRAM, Sleep, Multimedia, Infrastructure, RS485, USB, Arm, Workload, IAR, Embedded, Linux, VLP, PCI Express, DDR, PSA, ICS, CPU, Trust anchor, CIP, Internet of things, Video game

Renesas Electronics Corporation (TSE:6723), a premier supplier of advanced semiconductor solutions, today introduced a new 64-bit general-purpose microprocessor (MPU) for IoT edge and gateway devices that consumes significantly less power.

Key Points: 
  • Renesas Electronics Corporation (TSE:6723), a premier supplier of advanced semiconductor solutions, today introduced a new 64-bit general-purpose microprocessor (MPU) for IoT edge and gateway devices that consumes significantly less power.
  • These features make the device ideal for IoT applications such as home gateways, smart meters, and tracking devices.
  • “The RZ/G3S represents the next generation products that will extend our reach to the rapidly growing 5G IoT and Gigabit Wi-Fi 7 gateway markets.
  • The fast startup allows IoT devices, which frequently operate intermittently, to save power and significantly extend the runtime of battery-powered devices.

HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China

Retrieved on: 
Monday, January 8, 2024
IND, Sale, Research, Norovirus, Vaccine, Disease, Mortality, Virus-like particle, SHE, MD, Doctor of Philosophy, Investigational New Drug, VLP, Bioproduct, Safety, Pharmaceutical industry

HIL-216 includes VLPs for six of the most common norovirus genotypes, including GI.1, GII.2, GII.3, GII.4, GII.6, and GII.17.

Key Points: 
  • HIL-216 includes VLPs for six of the most common norovirus genotypes, including GI.1, GII.2, GII.3, GII.4, GII.6, and GII.17.
  • As part of the exclusive license agreement, Kangh will supply HIL-216 for use in HilleVax’s near-term clinical trials, including a Phase 1 trial that HilleVax expects to initiate in 2024.
  • “Our bivalent norovirus VLP vaccine candidate, HIL-214, remains the most advanced norovirus vaccine candidate in clinical development, and we are on-track to report topline safety and efficacy data in mid-2024 from our ongoing Phase 2b NEST-IN1 trial.
  • Kangh is also eligible to receive a single-digit tiered royalty on net sales outside of Greater China.

HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 3, 2024
PST, EST, Conference, Vaccine, VLP

BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 8, 2024 at 4:30 p.m. EST / 1:30 p.m. PST.

Key Points: 
  • BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 8, 2024 at 4:30 p.m. EST / 1:30 p.m. PST.
  • HIL-214, HilleVax’s investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion.

Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults

Retrieved on: 
Tuesday, December 12, 2023
MF59, Fever, Șaeș, RSV, Aes, Respiratory syncytial virus, Vaccine, Human, Ageing, Lance, Vaccination, Myalgia, CSL, VLP, Safety, Infection

SEATTLE, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced positive topline interim results from its Phase 2 clinical trial of IVX-A12 against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in older adults.

Key Points: 
  • “We’re delighted to announce positive topline interim data from our Phase 2 trial of IVX-A12, our potential first-in-class combination vaccine candidate against RSV and hMPV,” said Adam Simpson, Chief Executive Officer of Icosavax.
  • The trial enrolled 264 healthy older adults aged 60 to 85 years, of which 241 subjects were evaluable for immunogenicity.
  • Topline interim safety and immunogenicity data from this trial were generally consistent with the previously reported Phase 1 data for IVX-A12.
  • IVX-A12 induced robust immune responses against both RSV and hMPV at Day 28 across both formulations with and without adjuvant.

Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca

Retrieved on: 
Tuesday, December 12, 2023
Risk, RSV, AstraZeneca, Respiratory syncytial virus, Acquisition, Centerview Partners, Human, VLP, Vaccine, Patient, Infection

SEATTLE, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX) today announced it has entered into a definitive agreement pursuant to which AstraZeneca, through an acquisition subsidiary, will initiate a tender offer to acquire all of Icosavax’s outstanding shares for a price of $15.00 per share in cash at closing, plus a non-tradable contingent value right to receive up to $5.00 in cash, payable upon achievement of specified regulatory and net sales milestones.

Key Points: 
  • Subject to the satisfaction of the conditions in the merger agreement, the acquisition is expected to close in the first quarter of 2024.
  • With the addition of Icosavax’s Phase III-ready lead asset to our late-stage pipeline, we will have a differentiated, advanced investigational vaccine, and a platform for further development of combination vaccines against respiratory viruses.
  • The press release can be found at www.icosavax.com.
  • Centerview Partners LLC is serving as exclusive financial advisor to Icosavax and Latham & Watkins LLP is serving as legal counsel.